Your Valuation Multiple Is Set in December. Don't Wait.

Your practice valuation multiple is set in December. Year-end numbers drive your 2026 asking price. Don't mess this up.

What buyers are looking at right now: General dentistry practices are trading at 9-11x EBITDA in 2025 for platform deals, or 5-8x for add-on acquisitions. Specialty practices are 1.0-1.8x depending on type. Those multiples are stable. They're not climbing. But they're also not falling. You're in a balanced market.

The catch: Your multiple depends entirely on your back half performance. If you're flat year-over-year or declining in Q4, a buyer will rebase. That 10x multiple drops to 8.5x because the trend is wrong. Conversely, if your last two quarters show growth, you keep the premium multiple. This is why DSOs are pushing hard on Q4 case acceptance and production. They know buyers look at trailing twelve months.

Why this applies to you right now: It's mid-November. Your December production is what matters. Not 2024. Not Q1-Q3. December. New case production, case acceptance, collections activity. A strong finish changes your valuation math on January 1st.

Action: Run your numbers weekly through December. Review case acceptance daily. Push your team hard on collections. Not because you need the cash. But because your practice's price tag depends on the next seven weeks looking strong.

OPERATOR MATH

Let's calculate how your Q4 performance directly impacts your practice valuation.

Baseline Practice: Annual revenue: $1.2M. Annual EBITDA (earnings before interest, taxes, depreciation, amortization): $360,000 (30% margin, typical for well-run general practice). Current valuation multiple: 10x EBITDA (premium range for platform deals). Practice valuation: $360,000 x 10 = $3,600,000.

Scenario 1: Flat Q4 Performance

Q1-Q3 2025 revenue: $900,000 ($300K per quarter). Q4 2025 revenue: $300,000 (flat versus Q1-Q3 average). Total 2025 revenue: $1.2M (same as 2024). EBITDA: $360,000 (same margin).

Buyer perception: "This practice is stagnant. No growth trajectory. We're pricing this at a lower multiple." Adjusted multiple: 8.5x EBITDA (buyers discount flat or declining practices by 1.0-1.5x). New valuation: $360,000 x 8.5 = $3,060,000. Valuation loss versus baseline: $540,000.

You just lost $540,000 in practice value because Q4 was flat.

Scenario 2: Strong Q4 Growth

Q1-Q3 2025 revenue: $900,000. Q4 2025 revenue: $360,000 (20% growth versus Q1-Q3 average, driven by aggressive case acceptance and collections push). Total 2025 revenue: $1.26M. EBITDA: $378,000 (30% margin on higher revenue).

Buyer perception: "This practice is growing. Momentum is positive. We'll pay a premium." Adjusted multiple: 10.5x EBITDA (buyers pay 0.5-1.0x premium for practices showing consistent growth). New valuation: $378,000 x 10.5 = $3,969,000. Valuation gain versus baseline: $369,000.

You just added $369,000 in practice value by crushing Q4.

Net Swing: Strong Q4 versus flat Q4 = $909,000 valuation difference ($3,969,000 - $3,060,000). That's nearly $1 million in practice value determined by 90 days of performance.

How to Generate Strong Q4:

Increase case acceptance by 10%: If you typically present 100 treatment plans per quarter with 60% acceptance, you close 60 cases. Increase acceptance to 66% (10% relative increase), you close 66 cases. Additional revenue per case (average $5,000): 6 cases x $5,000 = $30,000 additional Q4 revenue.

Push outstanding collections: Typical practice has $80,000-$120,000 in outstanding accounts receivable. Aggressive collections campaign in November-December: recover an additional 10-15% of AR. Additional cash collected: $8,000-$18,000.

Add high-value cases: Focus on implant, crown, or cosmetic cases in Q4. Even 5 additional high-value cases ($6,000 each) = $30,000 additional revenue.

Total Q4 revenue boost: $30,000 (case acceptance) + $15,000 (collections) + $30,000 (high-value cases) = $75,000 additional Q4 revenue. New Q4 total: $375,000 (25% growth). New annual revenue: $1.275M. New EBITDA: $382,500. New valuation at 10.5x: $4,016,250. Additional value created: $416,250 versus baseline.

THE TAKEAWAY

Your Q4 performance determines whether buyers pay you $3M or $4M for your practice. That's a $1M swing driven by 90 days of focused execution. If you're even considering a sale in the next 2-3 years, treat Q4 like your audition.

Action steps this month: Pull your Q1-Q3 revenue and EBITDA. Calculate your run rate. Set a Q4 revenue target that's 15-20% above your Q1-Q3 average. Train your team on case acceptance for high-value procedures (crowns, implants, cosmetic). Offer year-end promotions: "Use your insurance benefits before they expire" messaging. Launch aggressive AR collections. Call every account over 60 days outstanding. Offer payment plans to close cases. Track weekly performance. Review case acceptance rates, collections, and new case starts every Monday. Celebrate wins with your team. Bonus structure tied to Q4 performance keeps everyone motivated.

If you're planning to sell in 2026-2027, a strong Q4 2025 sets your baseline valuation. Buyers will look at trailing twelve months (TTM) when they value your practice in early 2026. Make sure those twelve months show growth, not stagnation.